Doximity's recent earnings report has sparked discussions about its stock valuation, particularly in light of its significant AI investments. Following a revenue guidance miss for FY27, Doximity's stock price has dropped to around $20, raising questions about whether it is undervalued.
In its fiscal Q4 2026 earnings, Doximity reported a revenue of $145.4 million, marking a 5% year-over-year increase, and an adjusted EBITDA that surpassed expectations. However, the company's guidance for FY27 revenue fell short of Wall Street's consensus by approximately $13 million. This miss, combined with a 47% year-to-date decline in stock value, has led to increased scrutiny of its future growth potential, especially as the company embarks on an "AI investment year." CEO Jeff Tangney emphasized that while AI revenue contributions will be minimal initially, the company is investing heavily in AI tools and products, including a recent acquisition aimed at enhancing its presence in the pharma market.
Doximity's engagement metrics are promising, with a 30% increase in active prescribers year-over-year and significant adoption of its AI tools among health systems. Analysts remain divided in their outlook, with a consensus of 5 Buys, 5 Outperforms, and 12 Holds, reflecting uncertainty about the pace of AI monetization amidst soft pharma advertising budgets.
Looking ahead, the potential for Doximity's stock to recover hinges on its ability to convert increased engagement into revenue from pharma budgets. With a projected target of $31 by March 2031, Doximity could represent a compelling investment opportunity if it successfully navigates the challenges of its AI strategy and the broader market dynamics.